Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

Affiliations

¹ Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
² Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
³ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland.
⁴ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
⁵ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁶ Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁷ Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Canada, University of Toronto, Toronto, ON, Canada. Electronic address: roger.mcintyre@uhn.ca.

PMID: 34246008
PMCID: PMC8240444
DOI: 10.1016/j.psychres.2021.114086

Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

Joshua D Rosenblat et al. Psychiatry Res. 2021 Sep.

. 2021 Sep:303:114086.

doi: 10.1016/j.psychres.2021.114086. Epub 2021 Jun 29.

Affiliations

¹ Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
² Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
³ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland.
⁴ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
⁵ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁶ Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁷ Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Canada, University of Toronto, Toronto, ON, Canada. Electronic address: roger.mcintyre@uhn.ca.

PMID: 34246008
PMCID: PMC8240444
DOI: 10.1016/j.psychres.2021.114086

Abstract

Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in Ontario, Canada, during COVID-19 restrictions (from March 2020 - February 2021; n = 107), compared to patients who received treatment in the previous year (March 2019 - February 2020; n = 160). Both groups experienced significant and comparable improvements in depressive symptoms, suicidal ideation, and anxiety with repeated ketamine infusions. Effectiveness of IV ketamine was not attenuated during the COVID-19 period.

Keywords: Bipolar disorder; COVID-19; Major depression; Psychiatric services; Treatment-resistant depression.

PubMed Disclaimer

Figures

Fig 1 — **Fig. 1**
Changes in depressive symptoms (QIDS-SR16), suicidal ideation (QIDS-SR16 suicidal ideation item), anxiety symptoms (GAD-7), and functional disability (SDS) with four ketamine infusions in adults with treatment-resistant depression receiving treatment before (n = 160) and during (n = 107) the COVID-19 pandemic.

See this image and copyright information in PMC

References

1. Bartoli F., Riboldi I., Crocamo C., Di Brita C., Clerici M., Carrà G. Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis. Neurosci. Biobehav. Rev. 2017 doi: 10.1016/j.neubiorev.2017.03.010. - DOI - PubMed
1. Castro V.M., Gunning F.M., McCoy T.H., Perlis R.H. Mood disorders and outcomes of COVID-19 hospitalizations. Am. J. Psychiatry. 2021 doi: 10.1176/appi.ajp.2020.20060842. appi.ajp.2020.2. - DOI - PMC - PubMed
1. Hao F., Tan W., Jiang L., Zhang L., Zhao X., Zou Y., Hu Y., Luo X., Jiang X., McIntyre R.S., Tran B., Sun J., Zhang Z., Ho R., Ho C., Tam W. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav. Immun. 2020;87:100–106. doi: 10.1016/j.bbi.2020.04.069. - DOI - PMC - PubMed
1. Lee Y., Ragguett R.M., Mansur R.B., Boutilier J.J., Rosenblat J.D., Trevizol A., Brietzke E., Lin K., Pan Z., Subramaniapillai M., Chan T.C.Y., Fus D., Park C., Musial N., Zuckerman H., Chen V.C.H., Ho R., Rong C., McIntyre R.S. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and systematic review. J. Affect. Disord. 2018 doi: 10.1016/j.jad.2018.08.073. - DOI - PubMed
1. Maj M., Stein D.J., Parker G., Zimmerman M., Fava G.A., De Hert M., Demyttenaere K., McIntyre R.S., Widiger T., Wittchen H. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19:269–293. doi: 10.1002/wps.20771. - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

Affiliations

Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

Authors

Affiliations

Abstract

Figures

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources